4-[1,5-dihydro-6-fluoro-7-methoxy-3-(trifluoromethyl)-[2]benzothiopyrano[4,3-c]pyrazol-1-yl]benzenesulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[1,5-dihydro-6-fluoro-7-methoxy-3-(trifluoromethyl)-[2]benzothiopyrano[4,3-c]pyrazol-1-yl]benzenesulfonamide
• 英文别名: 4-[6-fluoro-7-methoxy-3-(trifluoromethyl)-5H-isothiochromeno[4,3-c]pyrazol-1-yl]benzenesulfonamide
• 化学式: C₁₈H₁₃F₄N₃O₃S₂
• 分子量: 459.445
• InChiKey: SCAUNTSWSFGRQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2-氟-3-甲氧基苯甲酸 在 盐酸 、 sodium hydroxide 、 dimethyl sulfide borane 、 sodium methylate 、 三氟乙酸 、 三氟乙酸酐 作用下， 以 甲醇 、 乙醚 、 乙醇 为溶剂， 反应 16.0h， 生成 4-[1,5-dihydro-6-fluoro-7-methoxy-3-(trifluoromethyl)-[2]benzothiopyrano[4,3-c]pyrazol-1-yl]benzenesulfonamide
  参考文献：
  名称：

  Conformationally restricted 1,5-diarylpyrazoles are selective COX-2 inhibitors

  摘要：

  Benzothiopyranopyrazoles and benzopyranopyrazoles containing either a sulfone or sulfonamide moiety were synthesized and tested for COX-1 and COX-2 inhibition. This new class of COX-2 selective inhibitors possess antiinflammatory activity in vivo. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00530-6

文献信息

• [EN] DERIVATIVES OF 2-(8,9-DIOXO-2,6-DIAZABICYCLO(5.2.0)NON-1(7)-EN-2-YL)ALKYL PHOSPHONIC ACID AND THEIR USE AS N-METHYL-D-ASPARTATE (NMDA) RECETOR ANTAGONISTS<br/>[FR] DERIVES D'ACIDE 2-(8,9-DIOXO-2,6-DIAZABICYCLO(5.2.0)NON-1(7)-EN-2-YL)ALKYL PHOSPHONIQUE ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR N-METHYL-D-ASPARTATE (NMDA)
  申请人：WYETH CORP

  公开号：WO2004092189A1

  公开（公告）日：2004-10-28

  Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R2 or R3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.

  提供了式（I）的化合物或其药用可接受的盐，其中R2或R3中至少有一个不是氢。本发明的化合物是N-甲基-D-天冬氨酸（NMDA）受体拮抗剂，对治疗受益于抑制NMDA受体的哺乳动物中存在的各种疾病是有用的。
• [EN] STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS MÉDICAMENT TRIOXACARCINE-ANTICORPS STABILISÉS ET UTILISATIONS DE CEUX-CI
  申请人：HARVARD COLLEGE

  公开号：WO2021252708A1

  公开（公告）日：2021-12-16

  Provided herein are antibody drug conjugates of Formula (I): G-R7(I) and pharmaceutically acceptable salts thereof, wherein G is a molecular payload; and R7 is - L-A-B, wherein L is a linking group, A is a conjugating group, and B is an antibody or antibody fragment. Also provided are methods of preparing the antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the antibody drug conjugates (e.g., compounds of Formula (III), novel trioxacarcins without an antibody conjugated thereto), pharmaceutical compositions thereof, and methods of their use and treatment.

  提供的是公式(I)的抗体药物偶联物：G-R7(I)及其药用可接受的盐，其中G是分子有效载荷；R7是-L-A-B，其中L是连接基团，A是偶联基团，B是抗体或抗体片段。还提供了制备抗体-药物偶联物的方法，药用可接受的组合物，以及其使用和治疗方法。还提供了抗体药物偶联物的前体（例如，公式(III)的化合物，没有抗体偶联的新型三氧杂卡菌素），其药用组合物，以及其使用和治疗方法。
• [EN] TRIOXACARCIN-ANTIBODY CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS TRIOXACARCINE-ANTICORPS ET UTILISATIONS ASSOCIÉES
  申请人：HARVARD COLLEGE

  公开号：WO2019032961A1

  公开（公告）日：2019-02-14

  Provided herein are trioxacarcin-antibody drug conjugates of Formula (I): and pharmaceutically acceptable salts thereof, wherein R7 is -L-B, wherein L is a linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing the antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin- antibody drug conjugates (e.g., compounds of Formula (II), novel trioxacarcins without an antibody conjugated thereto), pharmaceutical compositions thereof, and methods of their use and treatment.

  本发明提供了三氧杂卡林-抗体药物偶联物，其化学公式为(I)：以及药用可接受的盐，其中R7是-L-B，L是连接基团，B是抗体或抗体片段。还提供了制备抗体-药物偶联物的方法，药用可接受的组合物，以及其使用和治疗方法。进一步提供的是三氧杂卡林-抗体药物偶联物的前体（例如，化学公式为(II)的化合物，没有抗体偶联的新三氧杂卡林），其药用组合物，以及其使用和治疗方法。
• [EN] ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] ISOXAZOLINES EN TANT QU'INHIBITEURS DE L'HYDROLASE DES AMIDES D'ACIDES GRAS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2010135360A1

  公开（公告）日：2010-11-25

  The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

  本发明提供了式(I)的异噁唑啉FAAH抑制剂或其药用可接受形式，其中G、Ra、Rb、Rc和Rd中的每一个如本文所定义。本发明还提供了包括式(I)化合物或其药用可接受形式以及药用可接受赋形剂的药物组合物。本发明还提供了治疗FAAH介导疾病的方法，包括向需要的受试者施用式(I)化合物或其药用可接受形式的治疗有效量。
• Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of making them
  申请人：Baudy Bernhard Reinhardt

  公开号：US20060079679A1

  公开（公告）日：2006-04-13

  Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided: wherein: A is alkylenyl of 1 to 4 carbon atoms, or alkenylenyl of 2 to 4 carbon atoms; R 1 and R 2 are, independently, hydrogen or a C 5 to C 7 aryl optionally substituted with 1 to 2 substituents, independently, selected from the group consisting of —C(O)R 3 , halogen, cyano, nitro, hydroxyl, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy, with the proviso that at least one of R 1 and R 2 is not hydrogen; R 3 is, independently, hydrogen, —OR 4 , alkyl, aryl, or heteroaryl; R 4 is hydrogen, alkyl, aryl, or heteroaryl; R 5 and R 6 are, independently, hydrogen, alkyl, hydroxyl, alkoxy, or C 5 to C 7 aryl; wherein any R 3 to R 6 group having an aryl or heteroaryl moiety can optionally be substituted on the aryl or heteroaryl moiety with 1 to about 5 substituents, independently, selected from the group consisting of halogen, cyano, nitro, hydroxyl, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy. Methods of making these compounds as well as methods using the compounds for treating a variety of conditions are also disclosed.

  提供具有式（I）或其药学上可接受的盐的化合物： 其中：A是1到4个碳原子的烷基或2到4个碳原子的烯基； R1和R2分别是氢或C5到C7芳基，可选地被1到2个取代基（独立选择自—C（O）R3、卤素、氰基、硝基、羟基、C1-C6烷基和C1-C6烷氧基）取代，但R1和R2中至少有一个不是氢； R3独立地是氢、—OR4、烷基、芳基或杂环芳基； R4是氢、烷基、芳基或杂环芳基； R5和R6独立地是氢、烷基、羟基、烷氧基或C5到C7芳基； 其中任何具有芳基或杂环芳基部分的R3到R6基可以选择地在芳基或杂环芳基部分上被1到约5个取代基（独立选择自卤素、氰基、硝基、羟基、C1-C6烷基和C1-C6烷氧基）取代。还公开了制备这些化合物的方法以及利用这些化合物治疗各种疾病的方法。